An approved gene therapy restores vision in children born with a rare form of blindness. There are other gene therapies advancing through clinical trials that could one day treat — and potentially cure — people suffering from devastating diseases like sickle cell, hemophilia, and Duchenne muscular dystrophy, among others.

Overactive bladder is bothersome, but it is most definitely not a devastating disease. Yet Tuesday, the biotech firm Urovant Sciences announced plans to pursue clinical development of a gene therapy to treat people who have this troubling but by no means life-threatening condition.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy